- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07938918
Non-Invasive Screening for Embryo Chromosome Abnormalities Using Growth Patterns and Culture Fluid Analysis (PEARL 1)
Prediction of Embryo Aneuploidy Using Non-invasive Morphokinetics and Culture Media Readouts
For Couples undergoing in vitro fertilization (IVF), one of the most important decisions is choosing which embryo has the best chance of leading to a healthy pregnancy. Today, this often relies on a biopsy, where a few cells are removed from the embryo for genetic testing (PGT-A). This technique has shown high accuracy; however, this test is invasive, adds cost, and involves handling the embryo directly.
The Prediction of Embryo Aneuploidy using Non-invasive Morphokinetics and Culture Media Readouts (PEARL) Trial is testing a non-invasive alternative that combines two approaches. The first; time-lapse imaging using a camera-equipped incubator to continuously record how an embryo divides and grows, without ever removing it from its stable environment. The second; spent culture media testing by analyzing the fluid that the embryo grows in for biological signals (DNA fragments, microRNA, proteins, and metabolic byproducts) which the embryo releases as it develops.
By studying these two sources of information together, alongside each embryo's actual genetic result from standard PGT-A testing, we aim to find out whether imaging and fluid analysis, combined, can reliably predict whether an embryo is chromosomally normal (euploid) or abnormal (aneuploid) without needing a biopsy.
Taking part does not change a couple's standard IVF treatment. Embryos are cultured and tested exactly as they normally would be; the only difference is that imaging data and a small sample of fluid that would otherwise be thrown away are collected for research analysis. All embryo selection and transfer decisions continue to be based on the clinic's usual standard of care.
If successful, this approach could make embryo assessment safer, faster, and more affordable reducing the need for invasive testing in IVF, in Abu Dhabi and internationally.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Time-lapse imaging (TLI) enables continuous, non-invasive assessment of embryo development. Early cleavage timings (t2, t3), cell cycle durations (cc2, cc3), and synchrony measures (s2, s3) have been associated with developmental competence, while later morphokinetic events; compaction and blastocyst expansion, appear particularly informative for blastocyst quality and may carry signals related to chromosomal status.
In parallel, spent embryo culture media (SECM) studies report that cell-free DNA (cfDNA) fragments, microRNA expression patterns, metabolic profiles, and specific secreted proteins differ between embryos with divergent developmental and genetic outcomes, suggesting SECM as a complementary, non-invasive biomarker source.
However, methodological variability across studies; including inconsistent sample collection timing, inadequate contamination control, and heterogeneous assay platforms, limits reproducibility and has constrained clinical translation. Critically, no adequately powered, prospective study has yet integrated detailed morphokinetic profiling with multi-omic SECM assessment and validated the combined approach against preimplantation genetic testing for aneuploidy (PGT-A) as a reference standard.
The PEARL Trial addresses this gap through a large, prospective, standardized dataset combining TLI-derived morphokinetic parameters with multi-omic SECM analysis (cfDNA, microRNA, metabolomic, and proteomic markers), collected under controlled conditions to minimize pre-analytical variability. All embryos will undergo routine PGT-A per standard clinical protocol, providing ground-truth ploidy status against which combined predictive models will be evaluated.
The primary objective is to determine the correlation between integrated morphokinetic/SECM signatures and embryo ploidy, and to assess the predictive performance of a combined non-invasive model relative to PGT-A. Embryo culture and clinical decision-making will follow standard institutional protocols throughout, with TLI and SECM sampling embedded within existing laboratory workflows to avoid any deviation from standard-of-care embryo handling.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Dr. Lamiya Mohiyiddeen, MD, FRCOG
- Número de telefone: +971543676002
- E-mail: lamiya.mohiyiddeen@fakihivf.com
Estude backup de contato
- Nome: Fatma Bathawab, PhD
- Número de telefone: +971585707393
- E-mail: fatma.bathawab@fakihivf.com
Locais de estudo
-
-
-
Abu Dhabi, Emirados Árabes Unidos
- Recrutamento
- Fakih IVF Fertility Centre LLC
-
Contato:
- Fatma Bathawab, PhD
- Número de telefone: +971585707393
- E-mail: fatma.bathawab@fakihivf.com
-
Contato:
- Lamiya Mohiyiddeen, MD, FRCOG
- Número de telefone: +971543676002
- E-mail: lamiya.mohiyiddeen@fakihivf.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Participants will be selected from IVF patients attending the FAKIH IVF clinic in Abu Dhabi.
Descrição
Inclusion Criteria:
- Women aged 21-40 years undergoing IVF/ICSI cycles at Fakih IVF Centre.
- Embryos cultured in validated timelapse incubators to the blastocyst stage or until developmental arrest.
- Availability of spent embryo culture media (SECM) samples and preimplantation genetic testing for aneuploidy (PGT-A) results for blastocysts
Exclusion Criteria:
- Known parental chromosomal abnormalities identified prior to the IVF cycle.
- Missing or contaminated SECM samples for analysis
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Aneuploid Embryos
Embryo culture spent media collected and frozen, then for embryos which are identified as aneuploid by PGT-A, their frozen spent media and morphokinetics will be analyzed. |
This is an observation cohort. There are no interventions in this study. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
miRNA expression profiles
Prazo: Day 6 or 7 of embryo culture.
|
miRNA expression profiles of spent media from embryo culture. |
Day 6 or 7 of embryo culture.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Correlation between spent media analysis and morphokinetics
Prazo: Day 6 or 7 of embryo culture.
|
Correlation between spent media analysis and morphokinetics in PGT-A confirmed Aneuploid embryos. Spent media harvested within 24 hours of embryo removal from culture media. |
Day 6 or 7 of embryo culture.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Lamiya Mohiyiddeen, MD, FRCOG, Fakih IVF Abu Dhabi
- Investigador principal: Dr. Yasmin Sajjad, MD, FRCOG, DOWH, Fakih IVF Abu Dhabi
- Investigador principal: Dr. Michael Fakih, PhD, Fakih IVF Abu Dhabi
Publicações e links úteis
Publicações Gerais
- Vera-Rodriguez M, Diez-Juan A, Jimenez-Almazan J, Martinez S, Navarro R, Peinado V, Mercader A, Meseguer M, Blesa D, Moreno I, Valbuena D, Rubio C, Simon C. Origin and composition of cell-free DNA in spent medium from human embryo culture during preimplantation development. Hum Reprod. 2018 Apr 1;33(4):745-756. doi: 10.1093/humrep/dey028.
- Chen S, Wang L, Hu Y, Yao Y, Gao F, Chang C, Zhang L, Huang H, Lu D, Xu C. Noninvasive preimplantation genetic testing for aneuploidy using blastocyst spent culture medium may serve as a backup of trophectoderm biopsy in conventional preimplantation genetic testing. BMC Med Genomics. 2025 Feb 21;18(1):34. doi: 10.1186/s12920-025-02106-7.
- Bracewell-Milnes T, Saso S, Abdalla H, Nikolau D, Norman-Taylor J, Johnson M, Holmes E, Thum MY. Metabolomics as a tool to identify biomarkers to predict and improve outcomes in reproductive medicine: a systematic review. Hum Reprod Update. 2017 Nov 1;23(6):723-736. doi: 10.1093/humupd/dmx023.
- Kamijo S, Hamatani T, Sasaki H, Suzuki H, Abe A, Inoue O, Iwai M, Ogawa S, Odawara K, Tanaka K, Mikashima M, Suzuki M, Miyado K, Matoba R, Odawara Y, Tanaka M. MicroRNAs secreted by human preimplantation embryos and IVF outcome. Reprod Biol Endocrinol. 2022 Aug 30;20(1):130. doi: 10.1186/s12958-022-00989-0.
- Li J, Liu Y, Qian Y, Zhang D. Noninvasive preimplantation genetic testing in assisted reproductive technology: current state and future perspectives. J Genet Genomics. 2020 Dec 20;47(12):723-726. doi: 10.1016/j.jgg.2020.11.007. Epub 2021 Jan 26.
- Kosteria I, Anagnostopoulos AK, Kanaka-Gantenbein C, Chrousos GP, Tsangaris GT. The Use of Proteomics in Assisted Reproduction. In Vivo. 2017 May-Jun;31(3):267-283. doi: 10.21873/invivo.11056.
- Rosenbluth EM, Shelton DN, Wells LM, Sparks AE, Van Voorhis BJ. Human embryos secrete microRNAs into culture media--a potential biomarker for implantation. Fertil Steril. 2014 May;101(5):1493-500. doi: 10.1016/j.fertnstert.2014.01.058. Epub 2014 Mar 12.
- Vergouw CG, Kieslinger DC, Kostelijk EH, Botros LL, Schats R, Hompes PG, Sakkas D, Lambalk CB. Day 3 embryo selection by metabolomic profiling of culture medium with near-infrared spectroscopy as an adjunct to morphology: a randomized controlled trial. Hum Reprod. 2012 Aug;27(8):2304-11. doi: 10.1093/humrep/des175. Epub 2012 May 30.
- Sturmey RG, Hawkhead JA, Barker EA, Leese HJ. DNA damage and metabolic activity in the preimplantation embryo. Hum Reprod. 2009 Jan;24(1):81-91. doi: 10.1093/humrep/den346. Epub 2008 Oct 3.
- Xin X, Wu S, Xu H, Ma Y, Bao N, Gao M, Han X, Gao S, Zhang S, Zhao X, Qi J, Zhang X, Tan J. Non-invasive prediction of human embryonic ploidy using artificial intelligence: a systematic review and meta-analysis. EClinicalMedicine. 2024 Oct 24;77:102897. doi: 10.1016/j.eclinm.2024.102897. eCollection 2024 Nov.
- Gimenez C, Conversa L, Murria L, Meseguer M. Time-lapse imaging: Morphokinetic analysis of in vitro fertilization outcomes. Fertil Steril. 2023 Aug;120(2):218-227. doi: 10.1016/j.fertnstert.2023.06.015. Epub 2023 Jun 25.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- FAKIH-2025-12
- DOH/ADHRTC/2026/500 (Outro identificador: Department of Health Abu Dhabi)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .